Cited by 359Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsClinical Laboratory Practices and Quality Control

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Vanderstichele, Hugo, Bibl, Mirko, Engelborghs, Sebastiaan, Le Bastard, Nathalie, Lewczuk, Piotr, Molinuevo, Jose Luis, Parnetti, Lucilla, Perret‐Liaudet, Armand, Shaw, Leslie M., Teunissen, Charlotte, Wouters, Dirk, Blennow, Kaj·2012·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2011.07.004

Open this paper in CoChat — free account

Abstract

Background: Numerous studies show that the cerebrospinal fluid biomarkers total tau (T‐tau), tau phosphorylated at threonine 181 (P‐tau 181P), and amyloid‐β (1‐42) (Aβ 1–42) have high diagnostic accuracy for Alzheimer's disease. Variability in concentrations for Aβ 1–42, T‐tau, and P‐tau 181P drives the need for standardization. Methods: Key issues were identified and discussed before the first meeting of the members of the Alzheimer's Biomarkers Standardization Initiative (ABSI). Subsequent ABSI consensus meetings focused on preanalytical issues. Results: Consensus was reached on preanalytical issues such as the effects of fasting, different tube types, centrifugation, time and temperature before storage, storage temperature, repeated freeze/thaw cycles, and length of storage on concentrations of Aβ 1–42, T‐tau, and P‐tau 181P in cerebrospinal fluid. Conclusions: The consensus reached on preanalytical issues and the recommendations put forward during the ABSI consensus meetings are presented in this paper.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2011.07.004

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Defining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citation
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citation
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
Doody, R. S., Stevens, J. E., Beck, C., Dubinsky, R., Kaye, J. A., Gwyther, L. P., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,708

Flagged first, then by citations

Show all 63 references

Research works printed but not linked: 3

Morris JC, 1999, Alzheimer's Disease, 11
10.1016/j.jalz.2011.03.008 · DOI · Paper page
DSlats.Hour‐to‐hour variability CSF biomarkers in AD patients. Presented at the Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD) July 10–15 2010 Honolulu Hawaii.

Sorted by citations

Items 101–200 of 359

Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease
Spiegel, J., Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Saint Louis, L. A., Randall, C., Butler, T., Xu, J., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150167 · Cited by 45
Self-citation
Data-Driven vs Consensus Diagnosis of MCI
Edmonds, E. C., Smirnov, D. S., Thomas, K. R., Graves, L. V., Bangen, K. J., Delano‐Wood, L., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2021) · Neurology · doi:10.1212/wnl.0000000000012600 · Cited by 45
APOE 𝜀4‐related blood–brain barrier breakdown is associated with microstructural abnormalities
Reas, E. T., Solders, S. K., Tsiknia, A. A., Triebswetter, C., Shen, Q., Rivera, C. S., Andrews, M., Alderson‐Myers, A., & Brewer, J. B. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14302 · Cited by 45
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team
Arnerić, S. P., Batrla‐Utermann, R., Beckett, L. A., Bittner, T., Blennow, K., Carter, L., Dean, R. A., Engelborghs, S., Genius, J., Gordon, M. F., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160573 · Cited by 44
Self-citation
The effects of different familial Alzheimer’s disease mutations on APP processing in vivo
Þórðardóttir, S., Ståhlbom, A. K., Almkvist, O., Thonberg, H., Eriksdotter, M., Zetterberg, H., Blennow, K., & Graff, C. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0234-1 · Cited by 47
Self-citation
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Frick, E. A., Emilsson, V., Jónmundsson, Þ., Steindorsdottir, A. E., Johnson, E. C. B., Puerta, R., Dammer, E. B., Shantaraman, A., Cano, A. C., Boada, M., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00693-1 · Cited by 47
Intraventricular Hemorrhage Clearance in Human Neonatal Cerebrospinal Fluid
Mahaney, K. B., Buddhala, C., Paturu, M. R., Morales, D. M., Limbrick, D. D., & Strahle, J. M. (2020) · Stroke · doi:10.1161/strokeaha.119.028744 · Cited by 41
Misfolded alpha-synuclein detection by RT-QuIC in dementia with lewy bodies: a systematic review and meta-analysis
Peña‐Bautista, C., Kumar, R., Baquero, M., Johansson, J., Cháfer‐Pericás, C., Abelein, A., & Ferreira, D. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1193458 · Cited by 41
Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications
Bros, P., Delatour, V., Vialaret, J., Lalère, B., Barthélemy, N. R., Gabelle, A., Lehmann, S., & Hirtz, C. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1048 · Cited by 41
Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid
Bastos, P. A. D., Ferreira, R. M., Manadas, B. J., Moreira, P. I., & Vitorino, R. M. P. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1299682 · Cited by 40
Brain comorbidities in normal pressure hydrocephalus
Allali, G., Laidet, M., Armand, S., & Assal, F. (2017) · European Journal of Neurology · doi:10.1111/ene.13543 · Cited by 41
Amyloid‐associated depression and ApoE4 allele: longitudinal follow‐up for the development of Alzheimer's disease
Qiu, W. Q., Zhu, H., Dean, M., Liu, Z., Vu, L., Fan, G., Li, H., Mwamburi, M., Steffens, D. C., & Au, R. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4339 · Cited by 41
Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine
Chiasserini, D., Biscetti, L., Farotti, L., Eusebi, P., Salvadori, N., Lisetti, V., Baschieri, F., Chipi, E., Frattini, G., Stoops, E., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160298 · Cited by 40
Self-citation
Alzheimer's Disease Diagnosis Using Enhanced Inception Network Based on Brain Magnetic Resonance Image
Cui, Z., Gao, Z., Leng, J., Zhang, T., Quan, P., & Zhao, W. (2019) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm47256.2019.8983046 · Cited by 41
Large-scale plasma proteomic profiling unveils diagnostic biomarkers and pathways for Alzheimer’s disease
Heo, G., Xu, Y., Wang, E., Ali, M., Oh, H. S., Losada, P. M., Anastasi, F., Escalante, A. G., Puerta, R., Song, S., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00872-8 · Cited by 51
CSF biomarkers in neurodegenerative and vascular dementias
Llorens, F., Schmitz, M., Ferrer, I., & Zerr, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.003 · Cited by 44
The use of cerebrospinal fluid in biomarker studies
Teunissen, C. E., Verheul, C., & Willemse, E. A. J. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00001-0 · Cited by 40
Self-citation
Statistical tests and identifiability conditions for pooling and analyzing multisite datasets
Zhou, H., Singh, V., Johnson, S. C., Wahba, G., Initiative, T. A. D. N., Fleisher, A., Preda, A., Pierce, A., Mintz, A., Lerner, A. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719747115 · Cited by 38
Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment
García‐Gutiérrez, F., Marquié, M., Muñoz, N., Alegret, M., Cano, A. C., de Rojas, I., García‐González, P., Olivé, C., Puerta, R., Orellana, A., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1221401 · Cited by 40
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 42
Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment
Ahmad, S., Yang, W., Orellana, A., Frölich, L., de Rojas, I., Cano, A. C., Boada, M., Hernández, I., Hausner, L., Harms, A. C., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01542-4 · Cited by 41
Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease
Pan, C., Korff, A., Galasko, D. R., Ginghină, C., Peskind, E. R., Li, G., Quinn, J. F., Montine, T. J., Cain, K. C., Shi, M. Y., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143099 · Cited by 36
Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers
Hok‐A‐Hin, Y. S., Willemse, E. A. J., Teunissen, C. E., & del Campo, M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9706-0_2 · Cited by 34
Self-citation
High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer’s disease
Nuzzo, T., Mancini, A., Miroballo, M., Casamassa, A., Maio, A. D., Donati, G., Sansone, G., Gaetani, L., Paoletti, F. P., Isidori, A. M., et al. (2021) · Amino Acids · doi:10.1007/s00726-021-02943-7 · Cited by 36
Self-citation
Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease
Dicarlo, M., Pignataro, P., Zecca, C., Dell’Abate, M. T., Urso, D., Gnoni, V., Giugno, A., Borlizzi, F., Zerlotin, R., Oranger, A., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26946 · Cited by 37
Characterization of Acid Sphingomyelinase Activity in Human Cerebrospinal Fluid
Mühle, C., Huttner, H. B., Walter, S., Reichel, M., Canneva, F., Lewczuk, P., Gulbins, E., & Kornhuber, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062912 · Cited by 35
Self-citation
Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
Toombs, J., Foiani, M. S., Wellington, H., Paterson, R. W., Arber, C., Heslegrave, A., Lunn, M. P., Schott, J. M., Wray, S., & Zetterberg, H. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.02.005 · Cited by 35
Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy
Schirinzi, T., Sancesario, G. M., Lazzaro, G. D., Scalise, S., Colona, V. L., Imbriani, P., Mercuri, N. B., Bernardini, S., Lang, A. E., & Pisani, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1893-1 · Cited by 36
T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease
Haris, M., Yadav, S. K., Rizwan, A., Singh, A., Cai, K., Kaura, D., Wang, E., Davatzikos, C., Trojanowski, J. Q., Melhem, E. R., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.02.016 · Cited by 33
Different Profiles of Spatial Navigation Deficits In Alzheimer’s Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment
Laczó, M., Martinkovič, L., Lerch, O., Wiener, J. M., Kalinová, J., Matušková, V., Nedelská, Z., Vyhnálek, M., Hort, J., & Laczó, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.886778 · Cited by 34
Comparison of the telephone‐Montreal Cognitive Assessment (T‐MoCA) and Telephone Interview for Cognitive Status (TICS) as screening tests for early Alzheimer's disease
Chappelle, S. D., Gigliotti, C. M., Léger, G. C., Peavy, G. M., Jacobs, D. M., Banks, S. J., Little, E. A., Galasko, D. R., & Salmon, D. P. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13039 · Cited by 32
Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms
Doecke, J. D., Rembach, A., Villemagne, V. L., Varghese, S., Rainey‐Smith, S. R., Sarros, S., Evered, L. A., Fowler, C. J., Pertile, K. K., Rumble, R. L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170128 · Cited by 32
Self-citation
Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
Cicognola, C., Chiasserini, D., & Parnetti, L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00143 · Cited by 33
Self-citation
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients
Maio, A. D., Nuzzo, T., Gilio, L., Serra, M., Buttari, F., Errico, F., Rosa, A. D., Bassi, M. S., Morelli, M., Sasabe, J., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106203 · Cited by 30
Evaluation of Sodium (23Na) MR-imaging as a Biomarker and Predictor for Neurodegenerative Changes in Patients With Alzheimer’s Disease
Mohamed, S. A., Herrmann, K., Adlung, A., Paschke, N., Hausner, L., Frölich, L., Schad, L. R., Groden, C., & Kerl, H. U. (2021) · In Vivo · doi:10.21873/invivo.12275 · Cited by 30
The National Institute on Aging-Alzheimer’s Association research criteria for mild cognitive impairment due to Alzheimer’s disease: predicting the outcome
Guo, L., Alexopoulos, P., Eisele, T., Wagenpfeil, S., Kurz, A., & Perneczky, R. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0349-0 · Cited by 33
Validation of a Multiplex Assay for Simultaneous Quantification of Amyloid-β Peptide Species in Human Plasma with Utility for Measurements in Studies of Alzheimer's Disease Therapeutics
Lachno, D. R., Emerson, J. K., Vanderstichele, H., Gonzales, C., Martényi, F., Konrad, R. J., Talbot, J. A., Lowe, S. L., Oefinger, P. E., & Dean, R. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121075 · Cited by 29
Self-citation
Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
Park, S. A., Chae, W. S., Kim, H. J., Shin, H. S., Kim, S., Im, J. Y., Ahn, S. I., Min, K. D., Yim, S. J., Ye, B. S., et al. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000184 · Cited by 28
Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment
Cano, A. C., Antonio, E. E., Bernuz, M., Puerta, R., García‐González, P., de Rojas, I., Olivé, C., Pérez‐Cordón, A., Montrreal, L., Núñez‐Llaves, R., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01793-7 · Cited by 30
Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease
Nuzzo, T., Miroballo, M., Casamassa, A., Mancini, A., Gaetani, L., Nisticò, R., Eusebi, P., Katane, M., Homma, H., Calabresi, P., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140537 · Cited by 30
Self-citation
Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology
Rembach, A., Evered, L. A., Li, Q., Nash, T., Vidaurre, L., Fowler, C. J., Pertile, K. K., Rumble, R. L., Trounson, B. O., Maher, S., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0157-7 · Cited by 27
Prevalence of Alternative Diagnoses and Implications for Management in Idiopathic Normal Pressure Hydrocephalus Patients
Macki, M., Mahajan, A., Shatz, R. S., Air, E. L., Novikova, M. S., Fakih, M., Elmenini, J., Kaur, M., Bouchard, K. R., Funk, B. A., et al. (2020) · Neurosurgery · doi:10.1093/neuros/nyaa199 · Cited by 27
Analytical Aspects of Molecular Alzheimer’s Disease Biomarkers
Andréasson, U., Vanmechelen, E., Shaw, L. M. J., Zetterberg, H., & Vanderstichele, H. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.44 · Cited by 26
Self-citation
Plasma β-amyloid 1–42 reference values in cognitively normal subjects
Zecca, C., Tortelli, R., Panza, F., Arcuti, S., Piccininni, M., Capozzo, R., Barulli, M. R., Barone, R., Cardinali, R., Abbrescia, D. I., et al. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.06.006 · Cited by 28
Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma
Pérez‐Grijalba, V., Fandos, N., Canudas, J., Insua, D., Casabona, D., Lacosta, A. M., Montañés, M., Pesini, P., & Sarasa, M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160325 · Cited by 26
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25
Proficiency Testing Programs for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers
Mattsson, N., Andréasson, U., Carrillo, M. C., Persson, S., Shaw, L. M. J., Zegers, I., Zetterberg, H., & Blennow, K. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.41 · Cited by 24
Self-citation
Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease
Ahmad, S., Orellana, A., Köhler, I., Frölich, L., de Rojas, I., Gil, S., Boada, M., Hernández, I., Hausner, L., Bakker, M. H. M., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00680-9 · Cited by 27
State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia—A Short Review and Diagnostic Algorithm
Solje, E., Benussi, A., Buratti, E., Remes, A. M., Haapasalo, A., & Borroni, B. (2021) · Diagnostics · doi:10.3390/diagnostics11050788 · Cited by 27
Arterial stiffening acts synergistically with APOE genotype and AD biomarker status to influence memory in older adults without dementia
Bangen, K. J., Smirnov, D. S., Delano‐Wood, L., Wierenga, C. E., Bondi, M. W., Salmon, D. P., & Galasko, D. R. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00851-2 · Cited by 25
The South African Society of Psychiatrists (SASOP) Treatment Guidlelines for Psychiatric Disorders
Emsley, R. A., Flisher, A. J., Grobler, G. P., Seedat, S., & Szabo, C. P. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.942 · Cited by 25
Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples
Greco, V., Pieragostino, D., Piras, C., Aebersold, R. H., Wiltfang, J., Caltagirone, C., Bernardini, S., & Urbani, A. (2014) · PROTEOMICS · doi:10.1002/pmic.201300565 · Cited by 23
Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease
Niemantsverdriet, E., Goossens, J., Struyfs, H., Martin, J., Goeman, J., Deyn, P. P. D., Vanderstichele, H., & Engelborghs, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150953 · Cited by 23
Self-citation
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Cicognola, C., Chiasserini, D., Eusebi, P., Andréasson, U., Vanderstichele, H., Zetterberg, H., Parnetti, L., & Blennow, K. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0130-3 · Cited by 25
Self-citation
Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease
Farotti, L., Paciotti, S., Tasegian, A., Eusebi, P., & Parnetti, L. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1341312 · Cited by 25
Self-citation
A combination of total tau and neurofilaments discriminates between neurodegenerative and primary psychiatric disorders
Fourier, A., Formaglio, M., Kaczorowski, F., Mollion, H., Perret‐Liaudet, A., Sauvée, M., & Quadrio, I. (2020) · European Journal of Neurology · doi:10.1111/ene.14247 · Cited by 23
Self-citation
The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly people
Jacobs, T., Jacobson, S. R., Fortea, J., Berger, J. S., Vedvyas, A., Marsh, K., He, T., Gutiérrez‐Jiménez, E., Fillmore, N. R., Gonzalez, M., et al. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00435-2 · Cited by 27
Self-citation
Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians
Rosa‐Neto, P., Hsiung, G. R., Masellis, M., & participants, O. B. O. T. C. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt223 · Cited by 24
Alzheimer Disease Biomarker Testing in Cerebrospinal Fluid: A Method to Harmonize Assay Platforms in the Absence of an Absolute Reference Standard
Vanderstichele, H., Shaw, L. M. J., Vandijck, M. L. J., Jeromin, A., Zetterberg, H., Blennow, K., Teunissen, C. E., & Engelborghs, S. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.201830 · Cited by 22
Self-citation
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
Vanderstichele, H., Demeyer, L., Janelidze, S., Coart, E., Stoops, E., Mauroo, K., Herbst, V., François, C., & Hansson, O. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0265-7 · Cited by 22
Self-citation
BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols
Antonio, E. E., Rosende‐Roca, M., Pérez‐Cordón, A., Gil, S., Orellana, A., Cano, A. C., Alegret, M., Espinosa, A., Alarcón‐Martín, E., Valero, S., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210254 · Cited by 21
Association between lower body temperature and increased tau pathology in cognitively normal older adults
Blessing, E., Parekh, A., Betensky, R. A., Babb, J. S., Saba, N., Debure, L., Varga, A. W., Ayappa, I. A., Rapoport, D. M., Butler, T., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105748 · Cited by 22
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 22
Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform
Delaby, C., Muñoz, L., Torres, S., Nadal, A., Bastard, N. L., Lehmann, S., Lleó, A., & Alcolea, D. A. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.12.021 · Cited by 21
Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status
Reas, E. T., Triebswetter, C., Banks, S. J., & McEvoy, L. K. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01380-w · Cited by 21
“A subset of ADRC participants ( N = 70) underwent lum-ber puncture with standardized procedures, preanalytical preparation, and storage of cerebrospinal fluid in accordance with the recommended best practices [31].”
Method
The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer’s Disease
Engelborghs, S., & Bastard, N. L. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/bf03262201 · Cited by 20
Self-citation
The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis: The Italian Selfie
Sancesario, G. M., SINdem-ITALPLANED, F., Toniolo, S., Chiasserini, D., Santo, S. G. D., Zegeer, J., Bernardi, G., Musicco, M., Caltagirone, C., Parnetti, L., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160975 · Cited by 20
Self-citation
Establishment of combined diagnostic models of Alzheimer’s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS)
Fan, D., Jian, J.-M., Huang, S., Li, W., Shen, Y., Wang, Z., Zeng, G., Yi, X., Jin, W., Liu, Y.-H., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02016-7 · Cited by 20
Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts
(2022) · doi:10.3390/proteomes10030026 · Cited by 20
CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
Fagan, A. M. (2014) · Advances in Geriatrics · doi:10.1155/2014/302712 · Cited by 21
Cerebrospinal fluid levels of L‐glutamate signal central inflammatory neurodegeneration in multiple sclerosis
Bassi, M. S., Nuzzo, T., Gilio, L., Miroballo, M., Casamassa, A., Buttari, F., Bellantonio, P., Fantozzi, R., Galifi, G., Furlan, R., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15518 · Cited by 19
Spatial Pattern Separation Testing Differentiates Alzheimer’s Disease Biomarker-Positive and Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment
Laczó, M., Lerch, O., Martinkovič, L., Kalinová, J., Marková, H., Vyhnálek, M., Hort, J., & Laczó, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.774600 · Cited by 21
The CORCOBIA study: Cut-off points of Alzheimer’s disease CSF biomarkers in a clinical cohort
Puig‐Pijoan, A., García‐Escobar, G., Fernández‐Lebrero, A., Manero-Borràs, R. M., Sánchez‐Benavides, G., Navalpotro‐Gómez, I., Cascales‐Lahoz, D., Suárez‐Calvet, M., Grau‐Rivera, O., Boltes, A., et al. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2022.05.002 · Cited by 19
The MINT Sprint 2.0: A picture naming test for detection of naming impairments in Alzheimer's disease and in preclinical AD
Gollan, T. H., Garcia, D. L., Stasenko, A., Murillo, M., Kim, C. H., Galasko, D. R., & Salmon, D. P. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13381 · Cited by 19
A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Park, S. A., Kang, J.-H., Kang, E., Ki, C., Roh, J. H., Youn, Y. C., Kim, S. Y., & Kim, S. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.132 · Cited by 19
Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes
Weston, P. S. J., Paterson, R. W., Marc Modat, A., Burgos, N., Cardoso, M. J., Magdalinou, N. K., Lehmann, M., Dickson, J. C., Barnes, A., Bomanji, J. B., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.10.001 · Cited by 19
Pre-analytical phase in clinical chemistry laboratory
Puri, D., Neogi, S., Mehndiratta, M., & Gupta, S. (2016) · The Journal of Clinical and Scientific Research · doi:10.15380/2277-5706.jcsr.15.062 · Cited by 19
Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges
Kim, D., Kim, Y. S., Shin, D. W., Park, C., & Kang, J.-H. (2016) · Journal of Clinical Neurology · doi:10.3988/jcn.2016.12.4.381 · Cited by 20
Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real‐word study on aducanumab and lecanemab
Logroscino, G., Urso, D., Gnoni, V., Giugno, A., Vilella, D., Castri, A. D., Barone, R. M. E., Nigro, S. L., Zecca, C., Blasi, R. D., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16534 · Cited by 18
Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort
Alegret, M., Sotolongo‐Grau, Ó., Antonio, E. E., Pérez‐Cordón, A., Orellana, A., Espinosa, A., Gil, S., Jiménez, D., Ortega, G., Sanabria, Á., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00988-8 · Cited by 18
Mild behavioral impairment in early Alzheimer’s disease and its association with APOE and BDNF risk genetic polymorphisms
Matušková, V., Veverová, K., Jester, D. J., Maťoška, V., Ismail, Z., Sheardová, K., Horáková, H., Cerman, J., Laczó, J., Andel, R., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01386-y · Cited by 19
γ‐Secretase binding sites in aged and A lzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF A β
Liu, F., Xue, Z., Deng, S.-H., Xiong, K., Luo, X., Patrylo, P. R., Rose, G. M., Cai, H., Struble, R. G., Cai, Y., et al. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12159 · Cited by 18
Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches
Galasko, D. R. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00256 · Cited by 19
Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases
Willemse, E. A. J., & Teunissen, C. E. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-20579-3_7 · Cited by 18
Self-citation
Hypothesis Testing in Unsupervised Domain Adaptation with Applications in Alzheimer's Disease.
Zhou, H., Ravi, S. N., Ithapu, V. K., Johnson, S. C., Wahba, G., & Singh, V. (2016) · PubMed · Cited by 18
The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment
Marquié, M., García‐Gutiérrez, F., Orellana, A., Montrreal, L., de Rojas, I., García‐González, P., Puerta, R., Olivé, C., Cano, A. C., Hernández, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021371 · Cited by 19
Head-to-Head Comparison of Aptamer- and Antibody-Based Proteomic Platforms in Human Cerebrospinal Fluid Samples from a Real-World Memory Clinic Cohort
Puerta, R., Cano, A. C., García‐González, P., García‐Gutiérrez, F., Capdevila, M., de Rojas, I., Olivé, C., Blázquez-Folch, J., Sotolongo‐Grau, Ó., Miguel, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010286 · Cited by 17
The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research
Kansal, K., & Irwin, D. J. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.02.002 · Cited by 18
Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia
Álvarez, I., Díez-Fairén, M., Aguilar, M., González, J. M., Ysamat, M., Tartari, J. P., Cárcel, M., Alonso, Á., Brix, B., Arendt, P., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14658 · Cited by 17
Reliable New Biomarkers of Mitochondrial Oxidative Stress and Neuroinflammation in Cerebrospinal Fluid and Plasma from Alzheimer’s Disease Patients: A Pilot Study
Lorenzo, R. D., Zecca, C., Chimienti, G., Latronico, T., Liuzzi, G. M., Pesce, V., Dell’Abate, M. T., Borlizzi, F., Giugno, A., Urso, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167792 · Cited by 18
Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes
Chaumont, H., Kaczorowski, F., San‐Galli, A., Michel, P. P., Tressières, B., Roze, E. F., Quadrio, I., & Lannuzel, A. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.11.002 · Cited by 18
Donanemab eligibility in early Alzheimer's disease: A real-world study
Urso, D., Introna, A., Gnoni, V., Giugno, A., Vilella, D., Zecca, C., Blasi, R. D., Giannoni‐Luza, S., & Logroscino, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331243 · Cited by 16
Accelerating drug development for Alzheimer's disease through the use of data standards
Neville, J., Kopko, S., Romero, K., Corrigan, B., Stafford, B., LeRoy, E. C., Broadbent, S., Cisneroz, M., Wilson, E., Reiman, E. M., et al. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.03.006 · Cited by 16
Self-citation
Tutorial review for peptide assays: An ounce of pre-analytics is worth a pound of cure
Maurer, J., Grouzmann, E., & Eugster, P. J. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123904 · Cited by 15
Challenges in the Neuropathological Diagnosis of Dementias
Jellinger, K. A. (2012) · International Journal of Neuropathology · doi:10.7726/ijn.2013.1002 · Cited by 15
Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
Vanderstichele, H., Teunissen, C. E., & Vanmechelen, E. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00166-3 · Cited by 16
Self-citation
Potential sources of interference on Abeta immunoassays in biological samples
Vanderstichele, H., Stoops, E., Vanmechelen, E., & Jeromin, A. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt142 · Cited by 15
Self-citation
A systematic review of amyloid-β peptides as putative mediators of the association between affective disorders and Alzheimer׳s disease
Abbasowa, L., & Heegaard, N. H. H. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.050 · Cited by 15
Amyloid deposition in adults with drug‐resistant temporal lobe epilepsy
Fonseca, E., Lallana, S., Ortega, G., Cano, A. C., Sarria‐Estrada, S., Pareto, D., Quintana, M., Lorenzo‐Bosquet, C., López‐Maza, S., Gifreu, A., et al. (2024) · Epilepsia · doi:10.1111/epi.18142 · Cited by 15
Florbetapir positron emission tomography and cerebrospinal fluid biomarkers
Hake, A. M., Trzepacz, P. T., Wang, S., Yu, P., Case, M. G., Hochstetler, H. M., Witte, M. M., Degenhardt, E. K., Dean, R. A., & Initiative, A. D. N. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.03.002 · Cited by 14

Authors: Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., Wouters, D., & Blennow, K.
Affiliations: Fujirebio (Belgium) (BE)
Kliniken Essen-Mitte (DE)
University of Antwerp (BE)
Department of Neurology and Memory Clinic, Middelheim and Hoge Beuken Hospital Network Antwerp (ZNA) Antwerp Belgium
Universitätsklinikum Erlangen (DE)
Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clinic i Universitari Barcelona Spain
University of Perugia (IT)
Lyon 1 Université (FR)
University of Pennsylvania (US)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
University of Gothenburg (SE)
Corresponding author: Blennow, Kaj
ORCID: Engelborghs, Sebastiaan
Lewczuk, Piotr
Parnetti, Lucilla
Perret‐Liaudet, Armand
Shaw, Leslie M.
Teunissen, Charlotte
Blennow, Kaj
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2011-11-03
Volume: 8
Issue: 1
Pages: 65-73
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2011.07.004
OpenAlex: W2141318707
Cited by: 358
References: 63
Citations by year: 2026: 7 · 2025: 18 · 2024: 33 · 2023: 21 · 2022: 22 · 2021: 29 · 2020: 33 · 2019: 14 · 2018: 19 · 2017: 23 · 2016: 26 · 2015: 42 · 2014: 30 · 2013: 17 · 2012: 23
FWCI: 15.32
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Pure Amsterdam UMC (submittedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
Keywords: Alzheimer's disease, cerebrospinal fluid biomarkers
MeSH terms: Alzheimer Disease, Humans, Peptide Fragments, Quality Control, Reproducibility of Results, Biomarkers, Amyloid beta-Peptides, tau Proteins, Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks